Avatrombopag Combined With IST as First-line Treatment for SAA

Severe Aplastic Anemia Clinical Trial

Official title:

The Efficacy and Safety Study of Avatrombopag Combined With IST as First-line Treatment for Severe Aplastic Anemia, A Single-arm, Phase II Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05720234
• Other study ID #: AVA&IST-001
• Status: Recruiting
• Phase: Phase 2
• Start date: November 10, 2022
• Est. completion date: November 30, 2024

Study information

• Verified date: November 2022
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Xin Zhao, M.D
• Phone: 8613702041366
• Email: zhaoxin[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This single-center study aims to evaluate the early efficacy and safety of avatrombopag combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic anemia (SAA).

Description:

This is a single center, single arm, phase II clinical study. Fifty-three patients will be enrolled.

Treatment protocol is as follows: 1) Anti-human thymocyte porcine immunoglobulin (P-ATG 20mg/kg/d) or rabbit anti human thymocyte globulin (R-ATG 3.0mg/kg/d) was administered intravenously for 5 days; 2) Cyclosporine (CSA) is given at 3-5 mg/kg.d in divided doses for at least 6 months. The trough concentration is maintained at 150-250 ng/ml. 3) Avatrombopag is given orally at 60 mg once a day for patients with body weight ≥ 50 kg, and 40 mg orally once a day for patients with body weight<50 kg, for a total of 12 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 53
• Est. completion date: November 30, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patients with newly diagnosed severe aplastic anemia.

2. Men and women aged between 12 and 60.

3. Subjects must complete all screening assessments as outlined in the test protocol.

4. Able to swallow or administer orally.

5. Before the start of the research procedure, the patient or guardian should fully understand the research procedure and purpose and sign the informed consent form. If the patient's signature is not conducive to the treatment of the disease, the patient's immediate family should sign the informed consent form.

Exclusion Criteria:

1. Congenital bone marrow failure (eg. Fanconi anemia).

2. Accompanied by cytogenetic cloning changes (chromosomal karyotype and FISH detection found somatic cloning abnormalities; Simple -Y abnormality can be included in this study;) .

3. ATG or middle/high-dose cyclophosphamide was used in the past.

4. Previous treatment with cyclosporine or tacrolimus > 6 months.

5. The total course of treatment with TPO receptor agonists (including thrombopoietin, eltrombopag,hetrombopag and avatrombopag) was more than 1 month.

6. Serious infectious diseases (tuberculosis without effective control, pulmonary aspergillosis, viral infections).

7. AIDS patients.

8. Pregnant or breastfeeding, fertile but unwilling to take effective contraceptive measures.

9. Patients with malignant tumors who are not suitable for ATG treatment.

10. A newly diagnosed history of cardio/cerebral vascular thrombosis within 12 months.

11. Those who are assessed as unsuitable for inclusion by the investigator.

Related Conditions & MeSH terms

• Anemia
• Anemia, Aplastic
• Severe Aplastic Anemia

Intervention

Drug:
• avatrombopag
Patients with body weight =50kg were given 60mg/day and patients with body weight < 50kg were given 40mg/day for 12 weeks.

Locations

Country	Name	City	State
China	Institute of Hematology & Blood Diseases Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment response	Percentage of patients who achieves complete response(CR) at 12 weeks.	From the start of study treatment (Day1) to end of week 12.
Secondary	Treatment response	Percentage of patients achieving hematologic response (OR) at 12 weeks.	From the start of study treatment (Day1) to end of week 12.
Secondary	Treatment response	Percentage of patients achieving hematologic response and complete response (OR and CR) at 24 weeks.	From the start of study treatment (Day1) to end of week 24.
Secondary	Supportive treatment	The time of red blood cell or platelet recovery to transfusion independence.	From the start study treatment (Day1) up to transfusion independence.
Secondary	Incidence of Treatment-Emergent Adverse Events by CTCAE	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	From the start study treatment (Day1) up to week 12.
Secondary	Dose-effect relationship	Correlation between avatrombopag's serum concentration with total and complete hematological response rate.	From the start study treatment(Day1) up to week 24.
Secondary	Change of CD34+ cell	Change of CD34+ cells' proportion in bone marrow before and after avatrombopag treatment at week 12 and 24.	From the start study treatment(Day1) up to end of week 12 and 24.